Among those agents, the first orally available FPN inhibitor vamifeport (VIT-2763) is now in clinical trials for the treatment of β-thalassemia and sickle cell disease (Manolova et al., 2019; Nyffenegger et al., 2022). This evidence concerns the gene SLC40A1 and sickle cell disease.